BridgeBio Pharma, Inc. has achieved a significant milestone by filing a New Drug Application with the U.S. Food and Drug Administration for acoramidis, a potential treatment for ATTR-CM

Exelixis, Inc. and Arcus Biosciences have recently announced a collaboration for the clinical trial named STELLAR-009. This trial, a phase 1b/2 investigation,

Carmot Therapeutics Inc, a biotechnology firm in the clinical stage dedicated to developing transformative therapeutics for individuals facing metabolic diseases like obesity and diabetes

Ambio, Inc., a pioneering biotechnology company specializing in the development of innovative peptide drugs, biosimilars, bioequivalents, and other intricate generic drugs, announced today that the U.S. Food and Drug Administration

Fujirebio Holdings, Inc. and Sysmex Corporation jointly announced today the expansion of their contract development and manufacturing services

SciNeuro Pharmaceuticals, a biotech company in the clinical stage, has successfully concluded dosing in its Phase 1 study, focusing on the development of treatments for neurodegenerative diseases

ASC Therapeutics, a privately-owned biopharmaceutical company specializing in the development of in-vivo gene replacement, gene editing, and allogeneic cell therapies

REGENXBIO Inc. celebrated a major milestone as the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. This trial is investigating RGX-202, a novel

Ensysce Biosciences, Inc. and OncoZenge AB have recently announced the signing of a letter of intent (LOI) to explore a strategic collaboration for the accelerated

TOLREMO therapeutics AG has announced the initiation of its Phase 1 clinical trial, with the dosing of the first patient taking place. This trial is designed to assess the safety, tolerability,